| Lymphoma, Follicular
Zevalin vs Gazyva
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Zevalin vs Gazyva with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGazyva has a higher rate of injection site reactions vs Zevalin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gazyva but not Zevalin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Zevalin
Gazyva
At A Glance
IV infusion
Single course
CD20-directed radioimmunotherapy
IV infusion
Anti-CD20 monoclonal antibody
Indications
- Lymphoma, Follicular
- Chronic Lymphocytic Leukemia
- Lymphoma, Follicular
- Lupus Nephritis
Dosing
Lymphoma, Follicular Day 1: rituximab 250 mg/m2 IV; Day 7, 8, or 9: rituximab 250 mg/m2 IV then Y-90 Zevalin 0.4 mCi/kg IV over 10 minutes (platelets >=150,000/mm3) or 0.3 mCi/kg IV over 10 minutes (platelets 100,000-149,000/mm3, relapsed or refractory); maximum dose 32 mCi; single course.
Chronic Lymphocytic Leukemia 100 mg IV on day 1 and 900 mg on day 2 of Cycle 1, then 1,000 mg on days 8 and 15 of Cycle 1, and 1,000 mg on day 1 of Cycles 2-6 (28-day cycles) in combination with chlorambucil.
Lymphoma, Follicular 1,000 mg IV on days 1, 8, and 15 of Cycle 1, then 1,000 mg on day 1 of Cycles 2-6 or 2-8 in combination with chemotherapy; responding patients continue on 1,000 mg monotherapy every 2 months for up to 2 years.
Lupus Nephritis 1,000 mg IV at initial infusion (Dose 1), at Week 2 (Dose 2), at Week 24 (Dose 3), at Week 26 (Dose 4), then 1,000 mg every 6 months thereafter, in combination with standard therapy.
Contraindications
—
- Known hypersensitivity reaction (e.g., anaphylaxis) to obinutuzumab or any excipient
- Serum sickness with prior obinutuzumab use
Adverse Reactions
Most common (>=5%) Cytopenias (thrombocytopenia, neutropenia, anemia, leukopenia, lymphopenia), fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, pyrexia
Serious Prolonged and severe cytopenias (thrombocytopenia, anemia, lymphopenia, neutropenia), MDS/AML, serious infusion reactions, severe cutaneous and mucocutaneous reactions
Postmarketing Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, exfoliative dermatitis, infusion site erythema and ulceration, radiation injury
Most common (>=10%) Infusion-related reactions, neutropenia, thrombocytopenia, diarrhea, fatigue, upper respiratory tract infection, musculoskeletal pain
Serious Hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, infusion-related reactions, hypersensitivity reactions including serum sickness, tumor lysis syndrome, infections, neutropenia, thrombocytopenia, disseminated intravascular coagulation
Postmarketing Serum sickness
Pharmacology
Ibritumomab tiuxetan is a murine IgG1 kappa monoclonal antibody immunoconjugate that binds specifically to the CD20 antigen on pre-B and mature B lymphocytes and >90% of B-cell NHL; the covalently linked Y-90 chelate (tiuxetan) delivers targeted beta radiation, inducing cellular damage via free radical formation in CD20-expressing and neighboring cells.
Obinutuzumab is a humanized anti-CD20 IgG1 monoclonal antibody with reduced fucose content that mediates B-cell lysis via immune effector cell engagement (ADCC and ADCP), direct intracellular death signaling, and complement activation; its reduced fucose content confers greater ADCC activity than rituximab.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Zevalin.
Gazyva
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
No coverage data available for Zevalin.
Gazyva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
No coverage data available for Zevalin.
Gazyva
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Chronic Lymphocytic Leukemia (CLL)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZevalinView full Zevalin profile
GazyvaView full Gazyva profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.